Oshkosh Corporation Appoints Angela M. Ambrose Vice President, Government Operations
Alvotech and STADA are expanding their strategic alliance for biosimilars by extending their partnership to include AVT03, a biosimilar candidate for Prolia®/Xgeva® (denosumab). This medication targets osteoporosis and cancer-related bone loss. Under the agreement, Alvotech will handle development and manufacturing, while STADA will manage commercialization in Europe, including Switzerland and the UK, as well as selected countries in Central Asia and the Middle East.
The partnership also extends STADA's commercial rights for Humira® and Stelara® biosimilars to CIS countries in Central Asia. Alvotech regains commercial rights to AVT06, a proposed Eylea® biosimilar. This expansion builds on their successful collaboration, which has already launched Hukyndra®, a high-concentration Humira® biosimilar, in Europe.
- Expansion of strategic alliance to include AVT03, a biosimilar for Prolia®/Xgeva® (denosumab)
- STADA gains semi-exclusive commercial rights in Europe and exclusive rights in selected Central Asian and Middle Eastern markets
- Extension of STADA's commercial rights for Humira® and Stelara® biosimilars to CIS countries
- Alvotech regains commercial rights to AVT06, a proposed Eylea® biosimilar
- None.
![Oshkosh Corporation announced today that Angela M. Ambrose has joined the organization as vice president of government operations to lead global public policy. Ambrose brings more than two decades of combined legislative and executive branch experience to the company, most recently serving as vice president, government relations and communications for General Motors Defense. Prior, she held two private sector legislative roles, serving as the defense portfolio government relations lead within Accenture’s federal practice and as the chief congressional strategist for Northrop Grumman’s aerospace business. (Photo: Business Wire)](https://mms.businesswire.com/media/20240715147335/en/2183590/4/GMD-AngelaAmbrose107265-B-2-EDIT.jpg)
Oshkosh Corporation announced today that Angela M. Ambrose has joined the organization as vice president of government operations to lead global public policy. Ambrose brings more than two decades of combined legislative and executive branch experience to the company, most recently serving as vice president, government relations and communications for General Motors Defense. Prior, she held two private sector legislative roles, serving as the defense portfolio government relations lead within Accenture’s federal practice and as the chief congressional strategist for Northrop Grumman’s aerospace business. (Photo: Business Wire)
Ambrose served as a federal civil servant on the senior legislative liaison teams in the Office of the Director of National Intelligence and Department of Defense’s Joint Improvised Explosive Device Defeat Organization. She began her professional experience on Capitol Hill in the
“We are honored to welcome Angela to the
Ambrose earned a Bachelor of Arts degree in communications from
To learn more about Oshkosh Corporation please visit oshkoshcorp.com today.
About Oshkosh Corporation
At
®, ™ All brand names referred to in this news release are trademarks of Oshkosh Corporation or its subsidiary companies.
Forward Looking Statements
This news release contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including, without limitation, statements regarding the Company’s future financial position, business strategy, targets, projected sales, costs, earnings, capital expenditures, debt levels and cash flows, and plans and objectives of management for future operations, are forward-looking statements. When used in this news release, words such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “should,” “project,” “confident” or “plan” or the negative thereof or variations thereon or similar terminology are generally intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, assumptions and other factors, some of which are beyond the Company’s control, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include the cyclical nature of the Company’s fire apparatus, refuse and recycling collection and air transportation equipment markets, which are particularly impacted by the strength of
View source version on businesswire.com: https://www.businesswire.com/news/home/20240715147335/en/
Financial: Patrick Davidson
Senior Vice President, Investor Relations
920.502.3266
Media: Jennifer Stiansen
Vice President, Global Branding & Communications
240-500-6485
Source: Oshkosh Corporation
FAQ
What is the new biosimilar candidate AVT03 in the Alvotech-STADA partnership targeting?
How are responsibilities divided between Alvotech and STADA for AVT03?
In which regions will STADA have commercial rights for AVT03?